Phase1 trial of Panitumumab combined with S-1 and irrinotecan in advanced/metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2620191
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Panitumumab:Bi-weekly administration 6 mg/kg TS-1 is orally administered b.i.d. on days 1-14 and CPT-11 is intravenously administered on days 1,8 every 4 weeks S-1:Level1 65mg/m2 day1-14 Level2 80mg/m2 day1-14 CPT-11:Level1,2 125mg/m2, day1
Primary outcome(s): Maximum tolerated dose Recommended dose
Study Design: Single arm Non-randomized
创建时间：
2010-10-15
